Department of Woman's and Child's Health, University of Padova, 35128, Padua, Italy.
SickKids Inflammatory Bowel Disease Centre, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada.
Sci Rep. 2021 Mar 15;11(1):5945. doi: 10.1038/s41598-021-85399-9.
CARMIL2 is required for CD28-mediated co-stimulation of NF-κB signaling in T cells and its deficiency has been associated with primary immunodeficiency and, recently, very early onset inflammatory bowel disease (IBD). Here we describe the identification of novel biallelic CARMIL2 variants in three patients presenting with pediatric-onset IBD and in one with autoimmune polyendocrine syndrome (APS). None manifested overt clinical signs of immunodeficiency before their diagnosis. The first patient presented with very early onset IBD. His brother was found homozygous for the same CARMIL2 null variant and diagnosed with APS. Two other IBD patients were found homozygous for a nonsense and a missense CARMIL2 variant, respectively, and they both experienced a complicated postoperative course marked by severe infections. Immunostaining of bowel biopsies showed reduced CARMIL2 expression in all the three patients with IBD. Western blot and immunofluorescence of transfected cells revealed an altered expression pattern of the missense variant. Our work expands the genotypic and phenotypic spectrum of CARMIL2 deficiency, which can present with either IBD or APS, aside from classic immunodeficiency manifestations. CARMIL2 should be included in the diagnostic work-up of patients with suspected monogenic IBD.
CARMIL2 对于 CD28 介导的 T 细胞 NF-κB 信号转导的共刺激是必需的,其缺陷与原发性免疫缺陷以及最近非常早发的炎症性肠病 (IBD) 有关。在这里,我们描述了在 3 名儿科 IBD 患者和 1 名自身免疫性多内分泌综合征 (APS) 患者中发现的新型双等位基因 CARMIL2 变体。在诊断之前,他们均没有明显的免疫缺陷临床症状。第一位患者表现为非常早发的 IBD。他的哥哥被发现携带相同的 CARMIL2 无效变体,被诊断为 APS。另外两名 IBD 患者分别携带一个无义突变和错义突变的 CARMIL2 变体,他们都经历了复杂的术后病程,以严重感染为特征。肠活检的免疫染色显示所有 3 名 IBD 患者的 CARMIL2 表达减少。转染细胞的 Western blot 和免疫荧光显示,错义变体的表达模式发生了改变。我们的工作扩展了 CARMIL2 缺乏症的基因型和表型谱,除了经典的免疫缺陷表现外,它可以表现为 IBD 或 APS。CARMIL2 应该纳入疑似单基因 IBD 患者的诊断评估中。